Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 13/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 13/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 13/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 12/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 10/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3215004 | 1.00 | CHRM3 (0.42) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL14291316 | 0.99 | ALDH1A1 (0.41) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL1851798 | 0.84 | CHRM3 (0.40) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL1848860 | 0.84 | CHRM3 (0.40) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL1848858 | 0.84 | CHRM3 (0.40) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL1851800 | 0.84 | CHRM3 (0.40) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL1109782 | 0.80 | CHRM3 (0.41) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL1109790 | 0.80 | CHRM3 (0.41) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL1109780 | 0.80 | CHRM3 (0.41) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL4739830 | 0.80 | CHRM3 (0.41) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056565-A1 | Heterocyclic Derivatives as M3 Muscarinic Receptors | ARGENTA DISCOVERY LIMITED (GB) | 2010-03-04 | — | — | US | disclosed |
| WO-2010018352-A1 | HETEROCYCLIC COMPOUNDS USED IN THE TREATMENT OF DISEASES WHERE ENHANCED M3 RECEPTOR ACTIVATION IS IMPLICATED | ARGENTA DISCOVERY LIMITED (GB) | 2010-02-18 | — | — | WO | disclosed |
| EP-2121688-A1 | HETEROCYCLIC DERIVATIVES AS M3 MUSCARINIC RECEPTORS | Argenta Discovery Ltd (GB) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008099186-A1 | HETEROCYCLIC DERIVATIVES AS M3 MUSCARINIC RECEPTORS | ARGENTA DISCOVERY LIMITED (GB) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008023157-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS USEFUL AS M3-RECEPTOR MODULATORS | ARGENTA DISCOVERY LIMITED (GB) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008023157-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS USEFUL AS M3-RECEPTOR MODULATORS | ARGENTA DISCOVERY LIMITED (GB) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056565-A1 | Heterocyclic Derivatives as M3 Muscarinic Receptors | CHRM2, CHRM3, CHRM1 | CHRM3 2/4885CHRM2 1/4885CHRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.